<DOC>
	<DOC>NCT00207077</DOC>
	<brief_summary>The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).</brief_summary>
	<brief_title>Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Measurable disease Life expectancy of at least 3 months Must have at least one prior chemotherapy containing a platinum Known or documented brain metastases Prior cetuximab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>